Related references
Note: Only part of the references are listed.Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
Alessandro Rambaldi et al.
CANCER (2020)
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Amandeep Salhotra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
Franco Locatelli et al.
LEUKEMIA (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
Treatment of Aggressive B Cell Lymphomas: Updates in 2019
Patrizia Mondello et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
Margaux Lejeune et al.
FRONTIERS IN IMMUNOLOGY (2020)
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Luke Coyle et al.
LEUKEMIA & LYMPHOMA (2020)
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma
Andreas Viardot et al.
LEUKEMIA & LYMPHOMA (2020)
Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
Alessandro Rambaldi et al.
BLOOD ADVANCES (2020)
Controversies in the Treatment of Follicular Lymphoma
Kai Huebel et al.
HEMASPHERE (2020)
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
Anthony S. Stein et al.
ANNALS OF HEMATOLOGY (2019)
Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
Brice Mouttet et al.
HAEMATOLOGICA (2019)
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review
Seren Durer et al.
IMMUNOTHERAPY (2019)
CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
M.J. Dickinson et al.
HEMATOLOGICAL ONCOLOGY (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Persis J. Amrolia et al.
BLOOD (2019)
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial
Ann-Marie E. Broske et al.
BLOOD (2019)
Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
Deborah A. Katz et al.
BLOOD (2019)
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Krish Patel et al.
BLOOD (2019)
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Chi-Chung Li et al.
BLOOD (2019)
Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Nassim Djebli et al.
BLOOD (2019)
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Martin Hutchings et al.
BLOOD (2019)
Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504
Marc Schwartz et al.
BLOOD (2019)
Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial
Franck Morschhauser et al.
BLOOD (2019)
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji et al.
BLOOD (2019)
Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph plus ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial
Sabina Chiaretti et al.
BLOOD (2019)
First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3xCD20) in B-Cell Non-Hodgkin Lymphomas
Pieternella Lugtenburg et al.
BLOOD (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
HEMATOLOGY (2019)
Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab
Ibrahim Aldoss et al.
BLOOD (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).
Max Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Lia Gore et al.
BLOOD CANCER JOURNAL (2018)
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Sebastian Kobold et al.
FRONTIERS IN ONCOLOGY (2018)
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann et al.
BLOOD (2018)
Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Elias Jabbour et al.
CANCER (2018)
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
Jonathan Webster et al.
BLOOD (2018)
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
Arie Barlev et al.
ADVANCES IN THERAPY (2017)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy
Inga Nagel et al.
BLOOD (2017)
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu et al.
CLINICAL PHARMACOKINETICS (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant
Muhammad Waqas Khan et al.
CLINICAL CASE REPORTS (2016)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Patrick Schlegel et al.
HAEMATOLOGICA (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
Josee Golay et al.
JOURNAL OF IMMUNOLOGY (2014)
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival
Corrado Tarella et al.
PLOS ONE (2014)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
Raymund Buhmann et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
R. Handgretinger et al.
LEUKEMIA (2011)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Germinal center structure and function: Lessons from CD19
Robert H. Carter et al.
SEMINARS IN IMMUNOLOGY (2008)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
Share Paper
